New combo therapy aims to cut transfusions in MDS patients
NCT ID NCT04798339
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests two drugs together—canakinumab and darbepoetin alfa—in people with a lower-risk form of myelodysplastic syndromes (MDS) whose previous treatment stopped working. The goal is to see if the combination is safe and can help the body make more red blood cells, reducing the need for blood transfusions. About 13 adults with MDS who require regular transfusions will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory-Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?
- Can a Gene-Targeted pill turn the tide against a rare blood cancer?